103 related articles for article (PubMed ID: 16506265)
21. Placental and maternal serum inhibin-A and activin-A levels in Down's syndrome pregnancies.
Dalgliesh GL; Aitken DA; Lyall F; Howatson AG; Connor JM
Placenta; 2001; 22(2-3):227-34. PubMed ID: 11170828
[TBL] [Abstract][Full Text] [Related]
22. Maternal serum activin-A at 30-33 weeks in the prediction of preeclampsia.
Lai J; Pinas A; Syngelaki A; Poon LC; Nicolaides KH
J Matern Fetal Neonatal Med; 2013 May; 26(8):733-7. PubMed ID: 23205865
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of maternal serum and vaginal interleukin-6 levels in preterm labor.
Sozmen S; Mungan T; Micozkadioglu SD; Tapisiz OL
J Soc Gynecol Investig; 2005 May; 12(4):e1-6. PubMed ID: 15866107
[TBL] [Abstract][Full Text] [Related]
24. Serum and urine inhibin A but not free activin A are endocrine biomarkers of severe pre-eclampsia.
Hamar BD; Buhimschi IA; Sfakianaki AK; Pettker CM; Magloire LK; Funai EF; Copel JA; Buhimschi CS
Am J Obstet Gynecol; 2006 Dec; 195(6):1636-45. PubMed ID: 16959203
[TBL] [Abstract][Full Text] [Related]
25. First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes.
Cowans NJ; Spencer K; Meiri H
Prenat Diagn; 2008 Feb; 28(2):121-5. PubMed ID: 18186153
[TBL] [Abstract][Full Text] [Related]
26. Chronic fetal hypoxia increases activin A concentrations in the late-pregnant sheep.
Supramaniam VG; Jenkin G; Loose J; Wallace EM; Miller SL
BJOG; 2006 Jan; 113(1):102-9. PubMed ID: 16398778
[TBL] [Abstract][Full Text] [Related]
27. Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis.
Elsammak MY; Amin GM; Khalil GM; Ragab WS; Abaza MM
Clin Biochem; 2006 Jun; 39(6):623-9. PubMed ID: 16624274
[TBL] [Abstract][Full Text] [Related]
28. Abnormal concentration of maternal serum activin-A in gestational diseases.
Petraglia F; De Vita D; Gallinelli A; Aguzzoli L; Genazzani AR; Romero R; Woodruff TK
J Clin Endocrinol Metab; 1995 Feb; 80(2):558-61. PubMed ID: 7852520
[TBL] [Abstract][Full Text] [Related]
29. Quantitative fetal fibronectin screening in asymptomatic high-risk patients and the spectrum of risk for recurrent preterm delivery.
Kurtzman J; Chandiramani M; Briley A; Poston L; Das A; Shennan A
Am J Obstet Gynecol; 2009 Mar; 200(3):263.e1-6. PubMed ID: 19254585
[TBL] [Abstract][Full Text] [Related]
30. Obstetric outcomes in women with elevated maternal serum human chorionic gonadotropin.
Towner D; Gandhi S; El Kady D
Am J Obstet Gynecol; 2006 Jun; 194(6):1676-81; discussion 1681-2. PubMed ID: 16643816
[TBL] [Abstract][Full Text] [Related]
31. Placenta previa and the risk of preterm delivery.
Zlatnik MG; Cheng YW; Norton ME; Thiet MP; Caughey AB
J Matern Fetal Neonatal Med; 2007 Oct; 20(10):719-23. PubMed ID: 17763272
[TBL] [Abstract][Full Text] [Related]
32. Examination of maternal plasma erythropoietin and activin A concentrations with regard to circulatory erythroblast levels in normal and preeclamptic pregnancies.
Troeger C; Holzgreve W; Ladewig A; Zhong XY; Hahn S
Fetal Diagn Ther; 2006; 21(1):156-60. PubMed ID: 16354996
[TBL] [Abstract][Full Text] [Related]
33. Activin A and activin receptors in gestational tissue from preeclamptic pregnancies.
Manuelpillai U; Schneider-Kolsky M; Dole A; Wallace EM
J Endocrinol; 2001 Oct; 171(1):57-64. PubMed ID: 11572790
[TBL] [Abstract][Full Text] [Related]
34. Maternal serum ferritin at 11- to 13-week gestation in spontaneous early preterm delivery.
Beta J; Poon LC; Bakalis S; Mosimann B; Nicolaides KH
J Matern Fetal Neonatal Med; 2012 Oct; 25(10):1852-5. PubMed ID: 22468901
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of patients with abnormal glucose challenge test and normal oral glucose tolerance test results: comparison with normal and gestational diabetic patients.
Dudhbhai M; Lim L; Bombard A; Juliard K; Meenakshi B; Trachelenberg Y; Weiner Z
Am J Obstet Gynecol; 2006 May; 194(5):e42-5. PubMed ID: 16647897
[TBL] [Abstract][Full Text] [Related]
36. Circulating levels of inhibin A, inhibin B and activin A in normal and intrauterine growth restricted (IUGR) fetuses.
Morpurgo PS; Cetin I; Borgato S; Cortelazzi D; Nobile-Desantis MS; Vaghi I; Beck-Peccoz P
Eur J Obstet Gynecol Reprod Biol; 2004 Nov; 117(1):38-44. PubMed ID: 15474242
[TBL] [Abstract][Full Text] [Related]
37. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia.
Spencer K; Cowans NJ; Nicolaides KH
Prenat Diagn; 2008 Jan; 28(1):7-10. PubMed ID: 18000943
[TBL] [Abstract][Full Text] [Related]
38. Ratio of circulating follistatin and activin A reflects the severity of acute liver injury and prognosis in patients with acute liver failure.
Lin SD; Kawakami T; Ushio A; Sato A; Sato S; Iwai M; Endo R; Takikawa Y; Suzuki K
J Gastroenterol Hepatol; 2006 Feb; 21(2):374-80. PubMed ID: 16509861
[TBL] [Abstract][Full Text] [Related]
39. Activin a plasma levels at birth: an index of fetal hypoxia in preterm newborn.
Florio P; Perrone S; Luisi S; Longini M; Tanganelli D; Petraglia F; Buonocore G
Pediatr Res; 2003 Nov; 54(5):696-700. PubMed ID: 12904593
[TBL] [Abstract][Full Text] [Related]
40. Pentraxin 3 in plasma and vaginal fluid in women with preterm delivery.
Assi F; Fruscio R; Bonardi C; Ghidini A; Allavena P; Mantovani A; Locatelli A
BJOG; 2007 Feb; 114(2):143-7. PubMed ID: 17305891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
